

> 定義 & 臨床表現


# HIV/AIDS

定義 & 臨床表現

• Acute HIV: mono-like syndrome → rash, lymphadenopathy, fever, oral ulcers, pharyngitis, myalgias, diarrhea. Presents ~2–6 wk after infxn.

• AIDS: HIV + CD4 <200/mm3 _or_ AIDS-defining opportunistic infection (OI) or malignancy

流行病學

• ~1 million Americans living with HIV (1 in 8 unaware); ~36 million worldwide

• Highest at risk are men who have sex with men (MSM) and African Americans

• Routes: sexual (risk is 0.1–1% per sex act without ARV), IVDU, transfusions, needlesticks (0.3%), vertical (15–40% without ARV)

Prophylaxis (_NEJM_ 2015;373:2237; _Lancet_ 2016;387:53; _J Infect Dis_ 2018;218:16)

• **Preexposure** (PrEP): TDF/FTC qd effective & safe in high-risk, adherent populations. Use in heterosexuals or MSM with: (1) serodiscordant partner, (2) inconsistent condom use, or (3) STI within 6 mo; or IVDU with equipment sharing or high-risk for HIV (_JAMA_ 2019;321:2203). On-demand PrEP effective option for MSM (44–86% ↓). ✔ renal fxn, STIs, & HIV q3 mo.

• **Postexposure** (PEP): present <72 hr after high-risk exposure from HIV+ source (case-by-case decision if HIV status unknown). Test baseline HIV, STIs, HBV, HCV. Rx: 2 NRTIs (usually TDF/FTC) + RAL or DTG × 4 wk. Consider initiating PrEP.

• 治療 is prevention: early Rx of HIV ⊕ Pt prevents transmission to partners (_NEJM_ 2016;375:830). Risk of transmission with unprotected sex with undetectable viral load is ~0% (_JAMA_ 2016;316:171; _Lancet HIV_ 2018;5:e438).

Screening and Diagnosis

• Screen all ages 13–64 once in lifetime & every pregnancy. High risk (IVDU, sex workers, MSM >1 partner) screen annually (_JAMA_ 2018;320:379).

• **HIV Ab/p24Ag** (ELISA assay): ⊕ 1–12 wk after acute infxn; >99% Se; 1° screening test

• If ⊕, Ab differentiation assay confirms and differentiates HIV-1 vs. -2 (_MMWR_ 2013;62:489)

• **HIV RNA PCR viral load** in plasma; assay range is 20–10 million copies/mL; ~2% false ⊕, but usually low # copies; in contrast, should be very high (>750 k) in 1° infxn

• **CD4 count:** not a dx test, b/c can be HIV ⊕ with normal CD4 or be HIV ⊖ with low CD4

Approach to newly diagnosed HIV ⊕ Pt (_JAMA_ 2018;320:379)

• Document HIV infection; counsel re: 治療 options, adherence, & disclosure

• **Lab evaluation:** CD4 count, HIV VL & genotype, CBC with diff., Cr, lytes, LFTs, A1c, & fasting lipids; PPD or IGRA, toxo, syphilis, _Chlamydia_ & gonorrhea screens, Hep A/B/C serologies; G6PD (if PCP ppx), Pap smear/anal pap in ♀/♂; ± CMV IgG, baseline CXR

• **Initiate ARV early** (same day prior to labs/genotype and with _guidance from HIV specialist_) regardless of CD4 level because ↓ mortality (_NEJM_ 2015;373:795)

• Regimens include: 2 NRTI (eg, TAF + FTC) + _either_ int. inhib or boosted PI (eg, DRV/r)

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Common Antiretrovirals (ARVs)</b></p></td><td><p><b>Common Side Effects</b></p></td></tr><tr><td><p><b>NRTI</b></p></td><td><p>abacavir (ABC; Ziagen)</p><p>emtricitabine (FTC; Emtriva)</p><p>lamivudine (3TC; Epivir)</p><p>tenofovir (TAF or TDF)</p><p>zidovudine (AZT; Retrovir)</p></td><td><p><i>Class:</i> GI intol, lipoatrophy, lactic acidosis</p><p>ABC: hypersensitivity (3%), ✔ <b>HLA-B<a id="st12"></a><a href="text/part0011_split_008.html#sst12">*</a>5701</b></p><p>AZT: BM suppression (esp. macrocytic anemia)</p><p>TDF: renal toxicity</p><p>TAF: minimal renal toxicity</p></td></tr><tr><td><p><b>NNRTI</b></p></td><td><p>efavirenz (EFV; Sustiva)</p><p>etravirine (ETR; Intelence)</p><p>nevirapine (NVP; Viramune)</p><p>rilpivirine (RPV; Edurant)</p></td><td><p><i>Class:</i> rash, hepatitis, mixed CYP450 inducer/inhib</p><p>EFV: CNS effects (incl depression)</p><p>NVP: rash and hypersensitivity [risk factors are female, CD4 &gt;250, pregnancy (∴ avoid)]</p></td></tr><tr><td><p><b>PI</b></p></td><td><p>atazanavir (ATV; Reyataz)</p><p>darunavir (DRV; Prezista)</p><p>lopinavir/riton. (LPV/r; Kaletra)</p><p>ritonavir (RTV; Norvir)</p></td><td><p><i>Class:</i> GI intol; hepatotoxicity; inhibit CYP450 (caution with statins); T2DM; truncal obesity; hyperlipid (less with ATV); MI <span>(</span><span><i>NEJM</i></span> <span>2007;356:</span><span>1</span><span>723)</span></p><p>ATV: crystalluria → nephrolithiasis</p><p>DRV: rash (<b>1</b>0%); possible sulfa cross-reactivity</p></td></tr><tr><td><p><b>FI</b></p></td><td><p>enfuvirtide (T20; Fuzeon)</p></td><td><p>Injection site reaction</p></td></tr><tr><td><p><b>EI</b></p></td><td><p>maraviroc (MVC; Selzentry)</p></td><td><p>Dizziness, hepatotoxicity; ✔ CCR5 tropism assay</p></td></tr><tr><td><p><b>II</b></p></td><td><p>bictegravir (BIC; Biktarvy) dolutegravir (DTG; Tivicay)</p><p>elvitegravir (EVG; Vitekta)</p><p>raltegravir (RAL; Isentress)</p></td><td><p>Class: diarrhea &amp; other GI intol; ↑ CPK</p><p>DTG ↑ metformin levels; monitor glc</p><p>DTG a/w neural tube defects</p></td></tr><tr><td><p><b>B<a href="text/part0011_split_008.html#sst12">*</a></b></p></td><td><p>ritonavir (r); cobicistat (COBI)</p></td><td><p>Drug interactions (inhibit CYP450)</p></td></tr></tbody></table>

NRTI, nucleoside/tide reverse transcriptase inhibitor; NNRTI, nonnucleoside RTI; PI, protease inhibitor; FI, fusion inhibitor; EI, entry inhibitor (CCR5 antagonist); II, integrase inhibitor; [\*](text/part0011_split_008.html#st12)booster to give with other ARVs; several multiclass combination pills exist

• Initiation of ARVs may _transiently worsen_ existing OIs (TB, MAC, CMV, others) due to immune reconstitution inflammatory syndrome (IRIS). Prednisone during 1st 4 wk of ARVs ↓ risk for TB-associated IRIS (_NEJM_ 2018;379:1915).

Approach to previously established HIV ⊕ Pt

• **H&P** (mucocutaneous, neurocognitive, OIs, malignancies, STDs); meds

• **Review ARVs** (past and current); if any must be interrupted, _stop all_ to ↓ risk of resistance

• Failing regimen = unable to achieve undetectable viral load, ↑ viral load, ↓ CD4 count or 臨床deterioration (with detectable viral load consider genotypic or phenotypic assay)

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>OI Prophylaxis</b> <span>(<a href="https://aidsinfo.nih.gov/guidelines">https://aidsinfo.nih.gov/guidelines</a> &amp; <i>JAMA</i> 2018;320:379)</span></p></td></tr><tr><td><p><b>OI</b></p></td><td><p><b>Indication</b></p></td><td><p><b>1° Prophylaxis</b></p></td></tr><tr><td><p><b>Tuberculosis</b></p></td><td><p>⊕ PPD (≥5 mm)/IGRA <i>or</i> high-risk exposure</p></td><td><p>Rifampin × 4 mo (noninferior to INH, but ✔ for drug interactions) <i>or</i> INH + vit B<sub>6</sub> × 9 mo</p></td></tr><tr><td><p><b><i>Pneumocystis</i> <i>jiroveci</i> (PCP)</b></p></td><td><p>CD4 &lt;200/mm<sup>3</sup> <i>or</i> CD4 &lt;14% <i>or</i> thrush</p></td><td><p>TMP-SMX DS or SS qd or DS tiw <i>or</i> dapsone 100 mg qd <i>or</i> atovaquone 1500 mg qd <i>or</i> pentamidine 300 mg inh q4wk</p></td></tr><tr><td><p><b>Toxoplasmosis</b></p></td><td><p>CD4 &lt;100/mm<sup>3</sup> <i>and</i> ⊕ <i>Toxo</i> IgG</p></td><td><p>TMP-SMX DS qd <i>or</i> dapsone 50 mg qd + pyrimeth. 50 mg qwk + leucovorin 25 qwk</p></td></tr><tr><td><p><b>MAC</b></p></td><td colspan="2"><p>Ppx no longer rec. if effective ART initiated</p></td></tr><tr><td colspan="3"><p>Stop 1° prophylaxis if CD4 &gt;initiation threshold &gt;3–6 mo on ARVs</p></td></tr><tr><td colspan="3"><p>Stop 2° prophylaxis (maintenance therapy for prior OI; drugs and doses differ by OI) if 臨床resolution or stabilization and CD4 thresholds have been exceeded × 3–6 mo</p></td></tr></tbody></table>

COMPLICATIONS OF HIV/AIDS

<table><colgroup><col> <col></colgroup><tbody><tr><td><p><b>CD4 Count</b></p></td><td><p><b>Complications</b></p></td></tr><tr><td><p><b>Any CD4 count</b></p></td><td><p>Influenza, HAV, HBV, HPV, VZV, <i>S. pneumo</i>, TB</p></td></tr><tr><td><p>&lt;<b>500</b></p></td><td><p>Constitutional sx; noninfectious disease (CVD, bone, oncologic)</p><p>Mucocutaneous: Kaposi’s sarcoma; seborrheic dermatitis; oral hairy leukoplakia; lymphoma; candidiasis; HSV</p><p>Recurrent bacterial infections, TB (pulm and extrapulm); neurosyphilis</p></td></tr><tr><td><p>&lt;<b>200</b></p></td><td><p><i>PCP, Toxo, Bartonella, Crypto, Histo</i> (if endemic), <i>Coccidio</i></p></td></tr><tr><td><p>&lt;<b>50–100</b></p></td><td><p>CMV, MAC, CNS lymphoma, PML, death (&lt;50 is medical emergency)</p><p>Invasive aspergillosis, bacillary angiomatosis (dissem. <i>Bartonella</i>)</p></td></tr></tbody></table>

Fever

• 原因 (_Infect Dis Clin North Am_ 2007;21:1013)

### infxn (82–90%): MAC, **TB**, **CMV**, **early PCP**, _Histo_, _Crypto_, _Coccidio_, _Toxo_, endocarditis

### noninfectious: lymphoma, **drug reaction.** Non 1° HIV itself rarely (<5%) cause of fever.

• Workup: guided by CD4 count, signs and symptoms, epi, & exposures

CBC, chem, LFTs, BCx, CXR, UA, mycobact. & fungal cx, ✔ meds, ? ✔ chest & abd CT

CD4 <100–200 → serum crypto Ag, LP, urinary _Histo_ Ag, CMV PCR

pulmonary signs and symptoms → CXR; ABG; sputum for bacterial cx, PCP, AFB; bronchoscopy

diarrhea → stool cx, O&P, AFB; direct visualization with bx on colonoscopy

cytopenias → BM bx for, path & cx of aspirate including for mycobacteria & fungi

Cutaneous

• Seborrheic dermatitis; eosinophilic folliculitis; **warts** (HPV); HSV & VZV; MRSA skin & soft tissue infxns; scabies; candidiasis; eczema; prurigo nodularis; psoriasis; drug eruption; subungual onychomycosis (at nail bed)

• **Molluscum contagiosum** (poxvirus): 2–5 mm pearly papules with central umbilication

• **Kaposi’s sarcoma** (KSHV or HHV8): red-purple nonblanching nodular lesions

• **Bacillary angiomatosis** (disseminated _Bartonella_): friable violaceous vascular papules

Ophthalmologic

• **CMV retinitis** (CD4 usu <50); Rx: gan- or valganciclovir, ganciclovir implant or cidofovir

• HZV, VZV, **syphilis** (any CD4 count, _treat as neurosyphilis_) or _Toxo:_ CD4 usually <100

Oral

• **Aphthous ulcers; KS; thrush** (oral candidiasis): curd-like patches typically with burning or pain; **oral hairy leukoplakia:** painless proliferation of papillae with adherent white coating usually on lateral tongue, caused by EBV but not precancerous

Endocrine/metabolic

• Hypogonadism**;** adrenal insufficiency (CMV, MAC, TB, HIV or med-related); wasting **osteopenia/porosis** (at all CD4 counts); **fragility fractures**

• **Lipodystrophy:** central obesity, peripheral lipoatrophy, dyslipidemia, hyperglycemia

Cardiovascular (_JACC_ 2013;61:511)

• CAD (HIV incr risk indep of classic risk fx); dilated CMP; pulm HTN; pericarditis/effusion

• Higher rates of VTE, stroke, worse outcomes after MI (_JAIDS_ 2012;60:351; _Circ_ 2013;127:1767)

Pulmonary

<table><colgroup><col> <col></colgroup><tbody><tr><td><p><b>Radiographic Pattern</b></p></td><td><p><b>Common Causes</b></p></td></tr><tr><td><p><b>Normal</b></p></td><td><p>Early PCP</p></td></tr><tr><td><p><b>Diffuse interstitial infiltrates</b></p></td><td><p>PCP, TB, viral, or disseminated fungal</p></td></tr><tr><td><p><b>Focal consolidation or masses</b></p></td><td><p>Bacterial or fungal, TB, KS</p></td></tr><tr><td><p><b>Cavitary lesions</b></p></td><td><p>TB, non-TB mycobacteria, aspergillus, other fungal, bacterial (incl MRSA, <i>Nocardia, Rhodococcus</i>)</p></td></tr><tr><td><p><b>Pleural effusion</b></p></td><td><p>TB, bacterial or fungal, KS, lymphoma</p></td></tr></tbody></table>

• **_Pneumocystis jiroveci_ (PCP) pneumonia (CD4** <**200)** (_NEJM_ 1990;323:1444)

constitutional sx, fever, night sweats, dyspnea on exertion, nonproductive cough

CXR with interstitial pattern, ↓ PaO2, ↑ A-a ∇, ↑ LDH, ⊕ PCP sputum stain, ⊕ β-glucan

Rx if PaO2 >70: **TMP-SMX** 15–20 mg of TMP/kg divided tid, avg dose = DS 2 tabs PO tid

Rx if PaO2 <70 or A-a gradient >35: **prednisone** before 抗生素 (40 mg PO bid; ↓ after 5 d)

HIV smokers are much more likely to die from lung cancer than OI (_JAMA_ 2017;177:1613)

Gastrointestinal & hepatobiliary

• **Esophagitis:** _Candida_, CMV (solitary, lg serpiginous), HSV (multiple, small shallow), aphthous ulcers, pills; EGD if no thrush or no response to empiric antifungals

• **Enterocolitis:** _bacterial_ (esp. if acute: shigella, salmonella, _C. diff_); _protozoal_ (esp. if chronic: Giardia, Entamoeba, etc.); _viral_ (CMV, adeno); _fungal_ (histo); MAC; AIDS enteropathy; TB enteritis

• **GI bleeding:** CMV, KS, lymphoma, histo; **proctitis:** HSV, CMV, _LGV, N. gonorrhoeae_

• **Hepatitis:** HBV, HCV, CMV, MAC, TB, histo, drug-induced

• **AIDS cholangiopathy:** often a/w CMV or _Cryptosporidium or Microsporidium_ (at ↓ CD4)

Renal

• **HIV-assoc.** nephropathy (collapsing FSGS); nephrotoxic drugs (eg, TDF → prox tub dysfxn)

Hematologic/oncologic (_NEJM_ 2018;378:1029)

• **Anemia:** ACD, BM infiltration by infxn or tumor, drug toxicity, hemolysis

• **Leukopenia; thrombocytopenia** (bone marrow involvement, ITP); infection, ↑ **globulin**

• **Non-Hodgkin lymphoma:** ↑ frequency with any CD4 count, but incidence ↑ with ↓ CD4

• **CNS lymphoma:** CD4 count <50, EBV-associated

• **Kaposi’s sarcoma** (HHV-8): at any CD4 count, incidence ↑ b/c CD4 ↓, usu. MSM

_Mucocut._ (violacious lesions); _pulmonary_ (nodules, infiltrates, LAN); _GI_ (bleed, obstruct.)

• **Cervical/anal CA** (HPV high risk in MSM); ↑ rates of liver (a/w HBV/HCV), gastric

Neurologic

• **Meningitis** _Crypto_ (dx with CSF; serum CrAg 90% Se), bact (inc. _Listeria_), viral (HSV, CMV, 1° HIV), TB, histo, _Coccidio_, lymphoma; **neurosyphilis** (cranial nerve palsies)

• **Space-occupying lesions:** may present as HA, focal deficits or Δ MS. Workup: MRI, brain bx if suspect non-_Toxo_ etiology (_Toxo_ sero ⊖) or no response to 2 wk of empiric anti-_Toxo_ Rx (if _Toxo_, 50% respond by d3, 91% by d14; _NEJM_ 1993;329:995)

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td><p><b>Etiology</b></p></td><td><p><b>Imaging Appearance</b></p></td><td><p><b>Diagnostic Studies</b></p></td></tr><tr><td><p><b>Toxoplasmosis</b></p></td><td><p>Enhancing lesions, typically in basal ganglia (can be multiple)</p></td><td><p>⊕ <i>Toxo</i> serology (Se ~85%)</p></td></tr><tr><td><p><b>CNS lymphoma</b></p></td><td><p>Enhancing ring lesion (single 60% of the time)</p></td><td><p>⊕ CSF PCR for EBV</p><p>⊕ SPECT or PET scan</p></td></tr><tr><td><p><b>Progressive multifocal leukoencephalopathy (PML)</b></p></td><td><p>Multiple nonenhancing lesions in white matter</p></td><td><p>⊕ CSF PCR for JC virus</p></td></tr><tr><td><p><b>Other:</b> abscess, nocardiosis, crypto, TB, CMV, HIV</p></td><td><p>Variable</p></td><td><p>Biopsy</p></td></tr></tbody></table>

• **AIDS dementia complex:** memory loss, gait disorder, spasticity (usually at CD4 ↓)

• **Depression:** ↑ rates of suicide/depression

• **Myelopathy: infxn** (CMV, HSV), **cord compression** (epidural abscess, lymphoma)

• **Peripheral neuropathy:** meds, HIV, CMV, demyelinating

Disseminated _Mycobacterium avium_ complex (DMAC)

• Fever, night sweats, wt loss, HSM, diarrhea, pancytopenia. Enteritis and mesenteric lymphadenitis if CD4 <150, bacillemia if <50. Rx: clarithro/azithro + ethambutol ± rifabutin.

Cytomegalovirus (CMV)

• Usually reactivation with ↓ CD4. Retinitis, esophagitis, colitis, hepatitis, neuropathies, encephalitis. CMV VL may be ⊖. Rx: ganciclovir, valganciclovir, foscarnet or cidofovir.
